Damora Therapeutics, Inc. (DMRA)
NASDAQ
Closed
Oct 20, 2026
Day's Range
19.3052 wk Range
4.95Overview - DMRA - Damora Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
864.32M
P/E (Trailing)
-5.09
P/E (Forward)
-9.30
PEG Ratio
0.05
Price / Book
3.23
EV / EBITDA
-8.97
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-21.60%
Return on Equity
-99.74%
Ownership
Shares Outstanding
61.73M
Float
40.88M
Short % of Shares Outstanding
8.94%
Held by Insiders
8.41%
Held by Institutions
105.78%
Price stats
Beta
1.43
50-Day Avg
27.39
200-Day Avg
26.13
Analyst Consensus
10 analysts
Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - DMRA - Damora Therapeutics, Inc.
Peers - DMRA - Damora Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- DMRANASDAQDamora Therapeutics, Inc.1.24BMarket Cap+11.38%52-week change-5.09P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE54.66BMarket Cap+4.54%52-week change30.26P/E (Trailing)31.73%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.97BMarket Cap-110.32%52-week change37.78P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - DMRA - Damora Therapeutics, Inc.
About
Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hematologic disorders, with an emphasis on mutant calreticulin-driven myeloproliferative neoplasms. Its current pipeline centers on DMR-001, an investigational monoclonal antibody therapy for essential thrombocythemia,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
